Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Mesothelioma, Malignant 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Chondrosarcoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 58Radiotherapy 50Carmustine 23Carboplatin 18Filgrastim 17Chemotherapy, Adjuvant 17Irinotecan 12Surgical Procedures, Operative 11Peripheral Blood Stem Cell Transplantation 11O(6)-benzylguanine 10Magnetic Resonance Spectroscopy 10Drug Therapy 10Etoposide 9sargramostim 8Thiotepa 8Thalidomide 8Cyclophosphamide 8Bevacizumab 8Procarbazine 7Gene Expression Profiling 7Erlotinib Hydrochloride 7Radiation 6Everolimus 6Cisplatin 6motexafin gadolinium 5aldesleukin 5Topotecan 5Imatinib Mesylate 5Celecoxib 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × alanosine × Sarcoma × Clear all
NCT00075894 2009-01-13

Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas

National Cancer Institute (NCI)

Phase 1 Completed
18 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡